X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (1772) 1772
male (1066) 1066
acetamides - therapeutic use (1048) 1048
acetamides - adverse effects (1036) 1036
index medicus (978) 978
female (906) 906
linezolid (730) 730
adult (710) 710
middle aged (690) 690
pharmacology & pharmacy (602) 602
aged (490) 490
acetamides - administration & dosage (489) 489
treatment outcome (427) 427
animals (422) 422
oxazolidinones - therapeutic use (419) 419
oxazolidinones - adverse effects (413) 413
acetamides - pharmacology (394) 394
clinical neurology (289) 289
efficacy (278) 278
infectious diseases (278) 278
adolescent (276) 276
acetamides - pharmacokinetics (268) 268
microbiology (232) 232
anti-bacterial agents - therapeutic use (223) 223
psychiatry (221) 221
anti-infective agents - adverse effects (204) 204
dose-response relationship, drug (196) 196
young adult (196) 196
safety (194) 194
pharmacokinetics (189) 189
oxazolidinones - administration & dosage (187) 187
vancomycin (186) 186
double-blind method (180) 180
lacosamide (179) 179
epilepsy (176) 176
anti-bacterial agents - adverse effects (170) 170
anti-infective agents - therapeutic use (167) 167
neurosciences (167) 167
anticonvulsants - therapeutic use (164) 164
drug therapy (159) 159
rats (151) 151
analysis (150) 150
drug therapy, combination (150) 150
child (149) 149
retrospective studies (148) 148
double-blind (147) 147
aged, 80 and over (145) 145
gram-positive bacterial infections - drug therapy (140) 140
oxazolidinones - pharmacology (138) 138
staphylococcal infections - drug therapy (138) 138
care and treatment (136) 136
anticonvulsants - adverse effects (134) 134
neurology (133) 133
seizures (129) 129
medicine & public health (126) 126
partial-onset seizures (126) 126
time factors (126) 126
administration, oral (125) 125
therapy (125) 125
agomelatine (123) 123
internal medicine (122) 122
antidepressive agents - therapeutic use (121) 121
infections (119) 119
drug interactions (113) 113
medicine, general & internal (113) 113
health aspects (112) 112
hypnotics and sedatives - adverse effects (112) 112
randomized controlled trials as topic (111) 111
antidepressive agents - adverse effects (106) 106
antiepileptic drugs (105) 105
hypnotics and sedatives - therapeutic use (105) 105
child, preschool (104) 104
research (104) 104
depressive disorder, major - drug therapy (103) 103
tolerability (99) 99
mice (98) 98
toxicology (96) 96
dosage and administration (95) 95
immunology (95) 95
oseltamivir (95) 95
anti-bacterial agents - pharmacology (94) 94
oxazolidinones - pharmacokinetics (94) 94
risk factors (94) 94
drug administration schedule (93) 93
antidepressants (92) 92
anticonvulsants - administration & dosage (91) 91
acetamides - blood (89) 89
microbial sensitivity tests (88) 88
sleep (88) 88
vancomycin - therapeutic use (88) 88
epilepsy - drug therapy (85) 85
anti-bacterial agents - administration & dosage (84) 84
drugs (84) 84
infant (84) 84
major depressive disorder (83) 83
antiviral agents - therapeutic use (82) 82
clinical trials as topic (82) 82
prospective studies (79) 79
pediatrics (78) 78
sleep initiation and maintenance disorders - drug therapy (78) 78
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (1933) 1933
German (39) 39
Spanish (33) 33
Russian (25) 25
Japanese (22) 22
French (19) 19
Chinese (9) 9
Swedish (5) 5
Italian (4) 4
Danish (2) 2
Norwegian (2) 2
Turkish (2) 2
Bulgarian (1) 1
Czech (1) 1
Dutch (1) 1
Hungarian (1) 1
Polish (1) 1
Portuguese (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Epilepsy and Behavior, ISSN 1525-5050, 2017, Volume 71, Issue Pt A, pp. 73 - 78
... side effects was undertaken in patients with treated epilepsy participating in prospective audits with new antiepileptic drugs (AEDs... 
Neurology | Antiepileptic drug | Side effects | Prospective audit | Epilepsy | Psychiatric | Seizures | DEPRESSION | POPULATION | REFRACTORY EPILEPSY | MENTAL-RETARDATION | PSYCHIATRY | CLINICAL NEUROLOGY | INTELLECTUAL DISABILITY | JUVENILE MYOCLONIC EPILEPSY | BEHAVIORAL SCIENCES | PEOPLE | ANXIETY DISORDERS | FOCAL EPILEPSY | LEVETIRACETAM | Pregabalin - adverse effects | Prospective Studies | Pregabalin - therapeutic use | Humans | Medical Audit - methods | Middle Aged | Piracetam - adverse effects | Seizures - drug therapy | Male | Young Adult | Anticonvulsants - adverse effects | Acetamides - therapeutic use | Piracetam - therapeutic use | Sodium Channel Blockers - adverse effects | Acetamides - adverse effects | Aged, 80 and over | Sodium Channel Blockers - therapeutic use | Adult | Female | Retrospective Studies | Mental Disorders - diagnosis | Epilepsy - psychology | Fructose - adverse effects | Mental Disorders - chemically induced | Dibenzazepines | Anticonvulsants - therapeutic use | Pyridones | Fructose - therapeutic use | Epilepsy - diagnosis | Mental Disorders - psychology | Fructose - analogs & derivatives | Piracetam - analogs & derivatives | Adolescent | Epilepsy - drug therapy | Aged | Drug-Related Side Effects and Adverse Reactions - diagnosis | Drug-Related Side Effects and Adverse Reactions - psychology | Seizures - psychology | Drugs | Complications and side effects | Anticonvulsants | Comorbidity | Learning disabilities | Seizures (Medicine) | Mental illness | Depression, Mental
Journal Article
British Journal of Clinical Pharmacology, ISSN 0306-5251, 12/2017, Volume 83, Issue 12, pp. 2778 - 2788
...‐dose gemfibrozil (part I) or rifampicin (part II) in healthy male subjects. Results Gemfibrozil had comparatively small effects on selexipag (less than 2... 
pharmacokinetics | rifampicin | selexipag | CYP2C8 | drug interactions | gemfibrozil | PULMONARY ARTERIAL-HYPERTENSION | TREPROSTINIL | REPAGLINIDE | CLOPIDOGREL | CONCISE GUIDE | PHARMACOLOGY | TOLERABILITY | PROSTACYCLIN RECEPTOR AGONIST | PHARMACOLOGY & PHARMACY | INHIBITOR | Prodrugs - administration & dosage | Activation, Metabolic | Cytochrome P-450 CYP2C8 Inhibitors - administration & dosage | Acetates - adverse effects | Acetates - blood | Area Under Curve | Humans | Middle Aged | Pyrazines - administration & dosage | Antihypertensive Agents - administration & dosage | Half-Life | Male | Metabolic Clearance Rate | Gemfibrozil - adverse effects | Healthy Volunteers | Acetamides - blood | Young Adult | Rifampin - adverse effects | Drug Interactions | Acetamides - adverse effects | Cytochrome P-450 CYP2C8 Inducers - adverse effects | Adult | Cytochrome P-450 CYP2C8 - metabolism | Rifampin - administration & dosage | Gemfibrozil - administration & dosage | Cytochrome P-450 CYP2C8 Inducers - administration & dosage | Acetamides - pharmacokinetics | Risk Assessment | Cytochrome P-450 CYP2C8 Inhibitors - adverse effects | Antihypertensive Agents - pharmacokinetics | Antihypertensive Agents - adverse effects | Antihypertensive Agents - blood | Cross-Over Studies | Prodrugs - adverse effects | Acetates - administration & dosage | Prodrugs - pharmacokinetics | Pyrazines - pharmacokinetics | Adolescent | Pyrazines - adverse effects | Pyrazines - blood | Germany | Acetamides - administration & dosage | Acetates - pharmacokinetics | Metabolites | Gemfibrozil | Cytochrome P-450 | Nausea | Drug therapy, Combination | Rifampin | Fibric acids
Journal Article
Journal of antimicrobial chemotherapy, ISSN 0305-7453, 2012, Volume 67, Issue 2, pp. 473 - 477
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 06/2014, Volume 370, Issue 23, pp. 2169 - 2179
Journal Article
Sleep Medicine Reviews, ISSN 1087-0792, 2009, Volume 14, Issue 4, pp. 259 - 267
Journal Article
Cochrane Database of Systematic Reviews, ISSN 1469-493X, 2012, Volume 2012, Issue 4, p. CD002744
Background During epidemics, influenza attack rates in children may exceed 40%. Options for prevention and treatment currently include the neuraminidase... 
Enzyme Inhibitors | Lungs & airways | Antiviral Agents | Respiratory infections: influenza | Neuraminidase inhibitors | Randomized Controlled Trials as Topic | Zanamivir | Prevention | Oseltamivir | Infectious disease | Treatment | Influenza | Influenza, Human | Neuraminidase | Child health | Respiratory infections | Medicine General & Introductory Medical Sciences | MULTICENTER | EFFICACY | Humans | PANDEMIC INFLUENZA | Influenza, Human [drug therapy] | Antiviral Agents [therapeutic use] | Acetamides [adverse effects; therapeutic use] | MEDICINE, GENERAL & INTERNAL | Sialic Acids [adverse effects; therapeutic use] | Oseltamivir [therapeutic use] | PHARMACOKINETICS | Enzyme Inhibitors [therapeutic use] | Zanamivir [therapeutic use] | CLINICAL EFFECTIVENESS | DOUBLE-BLIND | B INFECTION | OSELTAMIVIR TREATMENT | Child | RESPIRATORY SYNCYTIAL VIRUS | Neuraminidase [antagonists & inhibitors] | INHALED ZANAMIVIR | Enzyme Inhibitors - adverse effects | Oseltamivir - adverse effects | Zanamivir - adverse effects | Antiviral Agents - therapeutic use | Oseltamivir - therapeutic use | Child, Preschool | Infant | Enzyme Inhibitors - therapeutic use | Zanamivir - therapeutic use | Zanamivir - analogs & derivatives | Antiviral Agents - adverse effects | Neuraminidase - antagonists & inhibitors | Influenza, Human - drug therapy | Influenza, Human - prevention & control
Journal Article